Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Gregory Martin Benson

Uwe Grether

Hans G Richter

Konrad H Bleicher

Sven Taylor

Rainer Eugen Martin

Bernd Kuhn

Jean-Marc Plancher

Minmin Yang

Song Feng

Markus Rudolph

Henrietta Dehmlow

Matthew Wright

Narendra Panday

Alexander Chucholowski

Eric Joseph Niesor

Franz Schuler

Xavier Marie Warot

The present invention relates to compounds of formula (I), as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein A, B, R, R, R, R, R, n, m and p have the significance defined herein.

Benzimidazole derivatives

This invention relates to novel cyclopentyl- and cycloheptylpyrazole derivatives of the formula I wherein A and Rto Rare as defined in the description and in the claims, as well as physiologically acceptable salts thereof. The invention relates also to compositions including these compounds and methods of using the compounds.

Cyclopentyl- and cycloheptylpyrazoles

This invention relates to novel indazole derivatives of formula I: wherein Rto Rare as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are FXR modulators and can be used as medicaments.

3-amino-indazole or 3-amino-4,5,6,7-tetrahydro-indazole derivatives

The invention is concerned with novel benzimidazole derivatives of formula (I) wherein Rto Rare as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds can be used as medicaments.

The invention is concerned with novel benzimidazole derivatives of formula (I) wherein A, n and Rto Rare as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds can be used as medicaments.

This invention relates to novel indazole or 4,5,6,7-tetrahydro-indazole derivatives of formula I wherein Rto Rare as defined in the description and in the claims, as well as physiologically acceptable salts thereof. These compounds are FXR modulators and can be used as medicaments.

Indazole or 4,5,6,7-tetrahydro-indazole derivatives

The invention is concerned with novel substituted benzimidazole derivatives of formula (I) wherein Rto Rare as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds can be used as medicaments.

Methyl-benzimidazole derivatives

This invention relates to novel carboxyl- or hydroxyl-substituted benzimidazole derivatives of formula (I) wherein Rto Rare as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to FXR and can be used as medicaments.

Carboxyl- or hydroxyl-substituted benzimidazole derivatives

The invention is concerned with novel substituted benzimidazole derivatives of formula (I) wherein Rto Rand X are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to FXR and can be used as medicaments.

Substituted benzimidazole derivatives

The invention is concerned with novel benzimidazole derivatives of formula (I) wherein Rto Rare as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds bind to Farnesoid-X-receptors (FXR) and can be used to treat diseases which are modulated by FXR agonists such as diabetes and dyslipidemia.

Growing community of inventors

Therwil, Switzerland

Gregory Martin Benson